Koers Cosmo Pharmaceuticals S.p.A Swiss Exchange
Aandelen
IT0004167463
Farmaceutische producten
slotkoers
Andere beurzen
|
||
- CHF | - |
|
Omzet 2023 | 96,72 mln. 104 mln. 93,38 mln. | Omzet 2024 * | 264 mln. 284 mln. 254 mln. | Marktkapitalisatie | 1,25 mld. 1,34 mld. 1,2 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | 1 mln. 1,08 mln. 965K | Nettowinst (verlies) 2024 * | 124 mln. 133 mln. 120 mln. | EV/omzet 2023 | 8,6 x |
Nettoliquiditeiten 2023 | 48,44 mln. 52,14 mln. 46,76 mln. | Nettoliquiditeiten 2024 * | 120 mln. 129 mln. 115 mln. | EV/omzet 2024 * | 4,28 x |
K/w-verhouding 2023 |
771
x | K/w-verhouding 2024 * |
10,1
x | Werknemers | - |
Dividendrendement 2023 |
3,65% | Dividendrendement 2024 * |
2,7% | Vrij verhandelbaar | 44,36% |
Recentste transcriptie over Cosmo Pharmaceuticals S.p.A
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Niall Donnelly
DFI | Director of Finance/CFO | 52 | 01-06-16 |
Chairman | 61 | 01-01-06 | |
Chief Tech/Sci/R&D Officer | 54 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 69 | 01-01-97 | |
Director/Board Member | 69 | 01-04-12 | |
Chairman | 61 | 01-01-06 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+48,39% | 779 mld. | |
-6,13% | 354 mld. | |
+20,61% | 333 mld. | |
+10,00% | 301 mld. | |
+19,23% | 249 mld. | |
-1,88% | 216 mld. | |
+11,61% | 214 mld. | |
+5,80% | 163 mld. | |
-2,50% | 159 mld. |
- Beurs
- Aandelen
- Koers COPN
- Koers